Comparison
GHK-Cu vs. Tirzepatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Cosmetic
Metabolic
CAS no.
49557-75-7
2023788-19-2
Molecular weight
340.4 g/mol
4813 g/mol
Half-life
no data
116 h
Sequence
GHKYXEGTFTSDYSIYLDKIAQKAFVQWLIAGGPSSGAPPPSMechanism of action
GHK-Cu
Endogenous tripeptide (glycyl-L-histidyl-L-lysine) that chelates copper(II) ions. In skin-cell models and skin biopsies an influence on collagen synthesis, antioxidant markers, gene-expression profiles and wound-healing processes has been described. In topical use in cosmetic studies, changes in various skin parameters have been reported.
Tirzepatide
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
3
3
of which in humans
1
3
Effects recorded
4
4
Open conflicts
1
0
Documented adverse events
2
2